• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Appili Therapeutics Inc (OP: APLIF )

    0.0280 +0.0042 (+17.65%)
    Streaming Delayed Price Updated: 3:22 PM EST, Nov 8, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Appili Therapeutics Inc

    < Previous 1 2 3 Next >
    InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Updates Shareholders on Equity Issuance and Shift to Debt Financing Strategy
    Via Investor Brand Network
    Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares
    From Aditxt, Inc.
    Via Business Wire
    BioMedNewsBreaks — Aditxt Inc. (NASDAQ: ADTX) Acquisition of Appili Therapeutics Moves Forward with Overwhelming Shareholder Approval
    Via Investor Brand Network
    Aditxt’s Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders
    From Aditxt, Inc.
    Via Business Wire
    BioMedNewsBreaks — Aditxt Inc. (NASDAQ: ADTX) Gains Support for Evofem Merger as Voting Agreements Secure Favorable Votes
    Via Investor Brand Network
    Aditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem
    From Aditxt, Inc.
    Via Business Wire
    InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) to Hold CEO-Led Update and Q&A Session Covering Company Developments
    Via Investor Brand Network
    Aditxt’s Target Acquisition Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission
    From Aditxt, Inc.
    Via Business Wire
    Aditxt To Host Virtual Stakeholder Update and Q&A Session on Friday, November 1, 2024, at 11:30 AM Eastern Time
    From Aditxt, Inc.
    Via Business Wire
    TinyGemsBreaks – Aditxt Inc. (NASDAQ: ADTX) Strengthens Leadership with Appointment of Governance Expert Sylvia Hermina to Board
    Via Investor Brand Network
    Sylvia Hermina Joins Aditxt’s Board of Directors, Elevating Leadership with Broader Perspectives
    From Aditxt, Inc.
    Via Business Wire
    InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Moves Closer to Evofem Acquisition with Final Investment Milestone
    Via Investor Brand Network
    Aditxt Completes Final Equity Investment and Key Milestone Under the Amended and Restated Merger Agreement with Evofem
    From Aditxt, Inc.
    Via Business Wire
    InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Hosts Virtual Fireside Chat to Discuss Evofem Acquisition and Future Strategic Plans
    Via Investor Brand Network
    InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Announces Acquisition Target Plans Special Meeting of Shareholders to Obtain Transaction Approval
    Via Investor Brand Network
    Aditxt’s Acquisition Target Appili Therapeutics Will Hold a Special Meeting of Shareholders on November 6, 2024, to Vote on the Transaction and Secure Appili’s Shareholder Approval
    From Aditxt, Inc.
    Via Business Wire
    InvestorNewsBreaks – Aditxt (NASDAQ: ADTX), Evofem Announce Completion of Third Parent Equity Investment Under Amended Merger Agreement
    Via Investor Brand Network
    InvestorNewsBreaks – Gaxos.ai Inc. (NASDAQ: GXAI) Announces Participation at the Upcoming Game Industry Conference
    Via Investor Brand Network
    InvestorNewsBreaks – Aditxt (NASDAQ: ADTX) Releases Shareholder Update, Plans for Remainder of 2024
    Via Investor Brand Network
    Aditxt Delivers Shareholder Update and 2024 Year-End Plan
    From Aditxt, Inc.
    Via Business Wire
    InvestorNewsBreaks – Aditxt (NASDAQ: ADTX) Acquisition Target Files Preliminary Proxy Seeking Stockholder Approval
    Via Investor Brand Network
    Aditxt to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 9th-11th, 2024
    From Aditxt, Inc.
    Via Business Wire
    TinyGemsBreaks – Aditxt Inc. (NASDAQ: ADTX), Appili Therapeutics (TSX: APLI) (OTC: APLIF) Enter Third Amending Agreement
    Via Investor Brand Network
    Aditxt Announces Third Amendment to Arrangement Agreement with Appili Therapeutics
    From Aditxt, Inc.
    Via Business Wire
    BioMedNewsBreaks — Aditxt Inc. (NASDAQ: ADTX), Appili Therapeutics Sign Second Amendent to Acquisition Agreement
    Via Investor Brand Network
    Aditxt Signs Second Amendment to the Arrangement Agreement with Appili Therapeutics, Targeting September 30 Closing of the Acquisition
    From Aditxt, Inc.
    Via Business Wire
    Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)
    From Aditxt, Inc.
    Via Business Wire
    Appili Therapeutics Announces Issuance of Patent for ATI-1701 Biodefense Vaccine Candidate to Protect Against Tularemia and Provides Update on Bridge Loan
    From Appili Therapeutics Inc.
    Via Business Wire
    Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2024
    From Appili Therapeutics Inc.
    Via Business Wire
    Appili Therapeutics’ Biodefense Vaccine Candidate ATI-1701 is Awarded Additional Funding from the U.S. Air Force Academy
    From Appili Therapeutics Inc.
    Via Business Wire
    < Previous 1 2 3 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.